A pilot pharmacogenomics study examining the influence of cytotoxic and metabolising genetic polymorphisms on chemotherapy toxicity and outcome in osteosarcoma
Background: Osteosarcoma is the most common malignant bone tumour in children and young people. Multi-agent MAP chemotherapy (Methotrexate, Adriamycin, cisPlatin) forms the backbone of standard treatment protocols but approximately 40% patients respond poorly to chemotherapy. It was hypothesized tha...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2013
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626104 |